Granite Point Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Granite Point Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-24,000	Closed	-$394K	–	192
2021 Q2	$394K	Hold	24,000	–	–	0.01%	145
2021 Q1	$530K	Sell	24,000 -26,000	-52%	-$709K	0.02%	163
2020 Q4	$1.55M	Hold	50,000	–	–	0.08%	107
2020 Q3	$1.02M	Sell	50,000 -50,000	-50%	-$878K	0.06%	121
2020 Q2	$1.54M	Buy	+100,000	New	+$1.15M	0.08%	96

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Granite Point Capital Management's TCRR Position: Q3 2021 in Review

Granite Point Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 24,000 shares — an estimated $394K sold.

Granite Point Capital Management first reported a position in TCRR in Q2 2020 and held it in 5 quarters. The position peaked at $1.55M in Q4 2020. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

Granite Point Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Granite Point Capital Management sold 24,000 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $394K.
Granite Point Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Granite Point Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $1.55M in Q4 2020.
117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Granite Point Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.